Tamsulosin - modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia
- 1 March 2006
- journal article
- Published by Future Medicine Ltd in Therapy
- Vol. 3 (2), 237-246
- https://doi.org/10.1586/14750708.3.2.237
Abstract
No abstract availableThis publication has 46 references indexed in Scilit:
- α1‐, α2‐ and β‐adrenoceptors in the urinary bladder, urethra and prostateBritish Journal of Pharmacology, 2006
- Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1‐adrenoceptor antagonistsBJU International, 2005
- State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaUrology, 2004
- α 1 -Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic HyperplasiaJournal of Urology, 2004
- Efficacy and safety of tamsulosin in the treatment of urological diseasesExpert Opinion on Pharmacotherapy, 2004
- Potential Role of α1-Adrenoceptors in the Aetiology of LUTSEuropean Urology Supplements, 2002
- TamsulosinDrugs, 2002
- Worldwide patterns of prevalence and mortality from benign prostatig hyperplasiaUrology, 1995
- α1-Adrenoceptor subtype selectivity of tamsulosin: Studies using livers from different speciesEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophyEuropean Journal of Pharmacology: Molecular Pharmacology, 1995